The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer

References

• JemalASiegelRWardEMurrayTXuJThunMJCancer StatisticsCA Cancer J Clin200757436617237035
   PubMed Web of Science ®Google Scholar
• GoldenbergDLeeJKochWMHabitual risk factors for head and neck cancerOtolaryngal Head Neck Surg2004131986993
   PubMed Web of Science ®Google Scholar
• HerreroRCastellsagueXPawlitaMHuman papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter studyJ Natl Cancer Inst2003951772118314652239
   PubMed Web of Science ®Google Scholar
• D’SouzaGAgrawalYHalpernJBodisonSGillisonMLOral sexual behaviors associated with prevalent oral human papillomavirus infectionJ Infect Dis2009199126312919320589
   PubMed Web of Science ®Google Scholar
• D’SouzaGKreimerARViscidiRCase-control study of human papillomavirus and oropharyngeal cancerN Engl J Med20073561944195617494927
   PubMed Web of Science ®Google Scholar
• FakhryCWestraWHLiSImproved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trialJ Natl Cancer Inst200810026126918270337
   PubMed Web of Science ®Google Scholar
• BonnerJAHarariPMGiraltJRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckN Engl J Med200635456757816467544
   PubMed Web of Science ®Google Scholar
• AstsaturovICohenRBHarariPMEGFR-targeting monoclonal antibodies in head and neck cancerCurr Cancer Drug Targets2006669171017168674
   PubMed Web of Science ®Google Scholar
• MehraRCohenRBBurtnessBAThe role of cetuximab for the treatment of squamous cell carcinoma of the head and neckClin Adv Hematol Oncol2008674275018997665
   PubMedGoogle Scholar
• PanikkarRPAstsaturovILangerCJThe emerging role of cetuximab in head and neck cancer: a 2007 perspectiveCancer Invest2008269610318181051
   PubMed Web of Science ®Google Scholar
• MessaCRussoFCarusoMGDi LeoAEGF, TGF-alpha, and EGF-R in human colorectal adenocarcinomaActa Oncol1998372852899677101
   PubMed Web of Science ®Google Scholar
• LaxIFischerRNgCNoncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificityCell Regul199123373451716463
   PubMedGoogle Scholar
• PrigentSALemoineNRThe type 1 (EGFR-related) family of growth factor receptors and their ligandsProg Growth Factor Res199241241355372
   PubMedGoogle Scholar
• OcPRhys-EvansPHModjtahediHEcclesSAThe role of c-erbB receptors and ligands in head and neck squamous cell carcinomaOral Oncol20023862764012167415
   PubMed Web of Science ®Google Scholar
• HambekMBaghiMBaumaunHZD 1839 inhibits phosphorylation of three different downstream signal transducers in head and neck cancerAnticancer Res2005251871187516158919
   PubMed Web of Science ®Google Scholar
• HauraEZhengZSongLCantorABeplerGActivated epidermal growth receptor-Stat3 signaling promotes tumor survival in vivo in non-small cell lung cancerClin Cancer Res2005118288829416322287
   PubMed Web of Science ®Google Scholar
• LoHHsuSAli-SayedMNuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathwayCancer Cell2005757558915950906
   PubMed Web of Science ®Google Scholar
• WannerGMayerCKehlbachRRodemannHDittmannKActivation of protein kinase C epsilon stimulates DNA repair via epidermal growth factor nuclear accumulationRadiother Oncol20088638339018037521
   PubMed Web of Science ®Google Scholar
• ChenDNirodiCThe epidermal growth factor receptor: a role in repair of radiation-induced DNA damageClin Cancer Res2007136555656018006754
   PubMed Web of Science ®Google Scholar
• RischinDPetersLHicksRPhase I trial of concurrent tirapazamine, cisplatin and radiotherapy in patients with advanced head and neck cancerJ Clin Oncol20011953554211208848
   PubMed Web of Science ®Google Scholar
• FriedmannBCaplinMHartleyJHochhauserDModulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor ZD1839Clin Cancer Res2004106476648615475435
   PubMed Web of Science ®Google Scholar
• YacoubAMcKinstryRHinmanDChungTDentPHaganMEpidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signalingRadiat Res2003159439435212643788
   PubMed Web of Science ®Google Scholar
• HuangSHarariPModulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics and tumor angiogenesisClin Cancer Res200062166217410873065
   PubMed Web of Science ®Google Scholar
• AngKKBerkeyBATuXImpact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinomaCancer Res2002627350725612499279
   PubMed Web of Science ®Google Scholar
• SheridanMTO’DwyerTSeymourCBMothersillCEPotential indicators of radiosensitivity in squamous cell carcinoma of the head and neckRadiat Oncol Investig19975180186
   PubMedGoogle Scholar
• DassonvilleOFormentoJLFrancoualMExpression of epidermal growth factor receptor and survival in upper aerodigestive tract cancerJ Clin Oncol199311187318788410112
   PubMed Web of Science ®Google Scholar
• RubinJGMelhemMFGoodingWELevels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survivalJ Natl Cancer Inst1988998824832
   Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A2004101133061331115329413
   PubMed Web of Science ®Google Scholar
• Loeffler-RaggJWitsch-BaumgartnerMTzankovALow incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinomaEur J Cancer20064210911116324836
   PubMed Web of Science ®Google Scholar
• Sheikh AliMAGunduzMNagatsukaHExpression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinomaCancer Sci2008991589159418754871
   PubMed Web of Science ®Google Scholar
• SokJCoppelliFThomasSMutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targetingClin Cancer Res2006125064507316951222
   PubMed Web of Science ®Google Scholar
• HarariPHuangSHead and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiationInt J Radiat Oncol Biol Phys20014942743311173137
   PubMed Web of Science ®Google Scholar
• HuangSBockJHarariPEpidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis and radiosensitivity in squamous cell carcinomas of the head and neckCancer Res1999591935194010213503
   PubMed Web of Science ®Google Scholar
• FengFLopezCNormolleDEffect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivoClin Cancer Res2007132512251817438112
   PubMed Web of Science ®Google Scholar
• FanZAntitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenograftsCancer Res199353463746428402640
   PubMed Web of Science ®Google Scholar
• BrownDAntiepidermal growth factor receptor antibodies augment cytotoxicity of chemotherapeutic agents on squamous cell carcinoma cell linesOtolaryngal Head Neck Surg20001227583
   PubMed Web of Science ®Google Scholar
• GoldsteinNIPrewettMZuklysKRockwellPMendelsohnJBiological efficacy of a chimeric antibody to the epidermal growth factor receptor ina human tumor xenograft modelClin Cancer Res19951131113189815926
   PubMed Web of Science ®Google Scholar
• BaselgaJThe EGFR as a target for anticancer therapy-focus on cetuximabEur J Cancer200137S16S2211597400
   PubMed Web of Science ®Google Scholar
• CiardielloFTortoraGA novel approach in the treatment of cancer: targeting the epidermal growth factor receptorClin Cancer Res2001729582957011595683
   PubMed Web of Science ®Google Scholar
• LiSSchmitzKJeffreyPWiltziusJKussiePFergusonFStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell2005730131115837620
   PubMed Web of Science ®Google Scholar
• SigismundSWoelkTPuriCClathrin-independent endocytosis of ubiquitinated cargosProc Natl Acad Sci U S A20051022760276515701692
   PubMed Web of Science ®Google Scholar
• Lopez-AlbaiteroAFerrisRImmune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancerArch Otolaryngol Head Neck Surg20071331277128118086972
   PubMed Web of Science ®Google Scholar
• KuraiJChikumiHHashimotoKAntibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell linesClin Cancer Res2007131552156117332301
   PubMed Web of Science ®Google Scholar
• Lopez-AlbaiteroALeeSCMorganSRole of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cellsCancer Immunol Immunother20095818551864
   Web of Science ®Google Scholar
• WirthLJ PMTishlerRBHaddadRIGoguenLClarkJRAllenAMPhase I study of panitumumab, chemotherapy and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early resultsJ Clin Oncol200826(May 20 suppl):abstr 6007.
   Google Scholar
• KuenenBWitteveenERuijterRA phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim resultsJ Clin Oncol200624(18S, June 20 suppl):abstr 3024.
   Google Scholar
• JohnsTGAdamsTECochranJRIdentification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptorJ Biol Chem2004279303753038415075331
   PubMed Web of Science ®Google Scholar
• LiSSchmitzKRJeffreyPDWiltziusJJKussiePFergusonKMStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell2005730131115837620
   PubMed Web of Science ®Google Scholar
• TalaveraAFriemannRGomez-PuertaSNimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformationCancer Res2009695851585919584289
   PubMed Web of Science ®Google Scholar
• SnyderLCAstsaturovIWeinerLMOverview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancerClin Colorectal Cancer20055Suppl 2S71S8016336752
   PubMedGoogle Scholar
• SchmiedelJBlaukatALiSKnochelTFergusonKMMatuzumab binding to EGFR prevents the conformational rearrangement required for dimerizationCancer Cell20081336537318394559
   PubMed Web of Science ®Google Scholar
• PfisterDGSuYBKrausDHConcurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigmJ Clin Oncol2006241072107816505426
   PubMed Web of Science ®Google Scholar
• LangerCJLiJWPatelUAPreliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)J Clin Oncol200826(May 20 suppl):abstr 6006.
   Web of Science ®Google Scholar
• KoutcherLFuryMWoldenSComparison of cisplatin and radiation to cetuximab and RT for locally advanced head and neck cancer: a preliminary analysisJ Clin Oncol20092715sabstr 6042.
   Google Scholar
• ArgirisAEGibsonMKHeronDEPhase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation, P and E in locally advanced head and neck cancerJ Clin Oncol2007Pt I. Vol 25, No. 18S (June 20 suppl):abstr 6051.
   Google Scholar
• WaneboHGhebremichaelMBurtnessBSpencerSRidgeJForastiereAPhase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303)J Clin Oncol2007Pt I, Vol 25, No. 18S (June 20 Supplement):abstr 6015.
   Google Scholar
• KiesMSHolsingerFCLeeJJInduction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trialJ Clin Oncol20102881419917840
   PubMed Web of Science ®Google Scholar
• VermorkenJBRemenarEvan HerpenCCisplatin, fluorouracil, and docetaxel in unresectable head and neck cancerN Engl J Med20073571695170417960012
   PubMed Web of Science ®Google Scholar
• PosnerMRHershockDMBlajmanCRCisplatin and fluorouracil alone or with docetaxel in head and neck cancerN Engl J Med20073571705171517960013
   PubMed Web of Science ®Google Scholar
• TishlerRBPosnerMRWirthLJCetuximab added to docetaxel, cisplatin, 5-fluorouracil induction chemotherapy in patients with newly diagnosed locally advanced head and neck cancer: a phase I studyJ Clin Oncol200826(May 20 suppl):abstr 6001.
   Web of Science ®Google Scholar
• MesiaRVazquezSGrauJJA single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin and 5-fluorouracil (TPF) as induction chemotherapy in patients with unresectable SCCHNJ Clin Oncol20092715S(suppl):abstr 6015.
   Web of Science ®Google Scholar
• RicheyLMShoresCGGeorgeJThe effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancerOtolaryngol Head Neck Surg20071369810317210342
   PubMed Web of Science ®Google Scholar
• MendenhallWMMendenhallCMMalyapaRSPaltaJRMendenhallNPRe-irradiation of Head and Neck CarcinomaAm J Clin Oncol20083139339818846001
   PubMed Web of Science ®Google Scholar
• TannockIFChemotherapy for head and neck cancerJ Otolaryngol198413991046202878
   PubMedGoogle Scholar
• Al-SarrafMChemotherapy strategies in squamous cell carcinoma of the head and neckCrit Rev Oncol Hematol198413233556085038
   PubMed Web of Science ®Google Scholar
• GlickJHZehngebotLMTaylorSGTChemotherapy for squamous cell carcinoma of the head and neck: A progress reportAm J Otolaryngol198013063236160777
   PubMedGoogle Scholar
• LeonXHittRConstenlaMA retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapyClin Oncol200517418424
   PubMed Web of Science ®Google Scholar
• BurtnessBGoldwasserMAFloodWPhase II randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group studyJ Clin Oncol20052386468865416314626
   PubMed Web of Science ®Google Scholar
• BourhisJRiveraFMesiaRPhase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neckJ Clin Oncol2006242866287216717293
   PubMed Web of Science ®Google Scholar
• VermorkenJBMesiaRRiveraFPlatinum based chemotherapy plus cetuximab in head and neck cancerN Engl J Med20083591116112718784101
   PubMed Web of Science ®Google Scholar
• HittRIrigoyenANunezJPhase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck: Spanish Head and Neck Cancer Group (TTCC)J Clin Oncol2007P I. Vol 25, No. 18S(June 20 suppl):abstr 6012.
   Google Scholar
• BaselgaJPfisterDCooperMPhase I studies of anti-epidermal growth factor receptor chimeric monoclonal antibody C225 alone and in combination with cisplatinJ Clin Oncol200018314904
   Web of Science ®Google Scholar
• RobertFEzekielMSpencerSPhase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancerJ Clin Oncol2001193234324311432891
   PubMed Web of Science ®Google Scholar
• ShinDMDonatoNJPerez-SolerREpidermal growth factor receptor targeted therapy with C225 and cisplatin in patients with head and neck cancerClin Cancer Res200171204121311350885
   PubMed Web of Science ®Google Scholar
• BaselgaJTrigoJMBourhisJPhase II mulitcenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neckJ Clin Oncol2005235568557716009950
   PubMed Web of Science ®Google Scholar
• HerbstRSArquetteMShinDMPhase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neckJ Clin Oncol2005235568557716009950
   PubMed Web of Science ®Google Scholar
• VermorkenJBTrigoJHittROpen-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapyJ Clin Oncol2007252171217717538161
   PubMed Web of Science ®Google Scholar
• VermorkenJHerbstRLeonXAmellalNBaselgaJOverview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapiesCancer20081122710271918481809
   PubMed Web of Science ®Google Scholar
• KnoedlerMKGaulerTMatzdorffAMulticenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHNJ Clin Oncol20092715S(suppl):abstr 6048.
   Web of Science ®Google Scholar
• KiesMGibsonMKimSCetuximab and bevacizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an interim analysisJ Clin Oncol200826(May 20 suppl):abstr 6072.
   Web of Science ®Google Scholar
• O’NeilBAllenRSpigelDHigh incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic historyJ Clin Oncol2007253644364817704414
   PubMed Web of Science ®Google Scholar
• ChungCMirakhurBChanECetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseN Engl J Med20083581109111718337601
   PubMed Web of Science ®Google Scholar
• YanoSKondoKYamaguchiMDistribution and function of EGR in human tissue and the effect of EGFR tyrosine kinase inhibitionAnticancer Res2003233639365014666659
   PubMed Web of Science ®Google Scholar
• FoersterCCursiefenCKruseFPersisting corneal erosion under cetuximab treatment: case reportCornea20082761261418520515
   PubMed Web of Science ®Google Scholar
• BoucheOBrixi-BenmansourHBertinATrichomegaly of the eyelashes following treatment with cetuximabAnn Oncol2005161711171215972283
   PubMed Web of Science ®Google Scholar
• SpecenierPKoppenCVermorkenJDiffuse punctate keratitis in a patient treated with cetuximab as monotherapy: letters to the editorAnn Oncol20071896196217442661
   PubMed Web of Science ®Google Scholar
• LiuZCarvajalMCarrawayKExpression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2 and ErbB3 in human ocular surface epitheliaCornea200120818511189010
   PubMed Web of Science ®Google Scholar
• NakamuraYSotozonoCKinoshitaSThe epidermal growth factor receptor: role in corneal wound healing and homeostasisExp Eye Res20017251151711311043
   PubMed Web of Science ®Google Scholar
• HarariPDurlandWChinnaiyanPHartigGImpact of the EGFR inhibitor C225 on wound healing in advanced head and neck cancer patients undergoing neck dissectionProc Am Soc Clin Oncol200322Abstract 881.
   Google Scholar
• DeanNWound healing complications with cetuximab therapyOtolaryngal Head Neck Surg200914161
   Google Scholar
• BarnesCJOhshiroKRayalaSKEl-NaggarAKKumarRInsulin-like growth factor receptor as a therapeutic target in head and neck cancerClin Cancer Res2007134291429917634559
   PubMed Web of Science ®Google Scholar
• YuZWeinbergerPMSasakiCPhosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancerCancer Epidemiol Biomarkers Prev20071655355817372251
   PubMed Web of Science ®Google Scholar
• AmornphimolthamPPatelVSodhiAMammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neckCancer Res2005659953996116267020
   PubMed Web of Science ®Google Scholar
• ZhangQThomasSMXiSSRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cellsCancer Res2004646166617315342401
   PubMed Web of Science ®Google Scholar
• XiSZhangQDyerKFSrc kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neckJ Biol Chem2003278315743158312771142
   PubMed Web of Science ®Google Scholar
• KoppikarPChoiSHEgloffAMCombined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinomaClin Cancer Res2008144284429118594011
   PubMed Web of Science ®Google Scholar
• KiesMGhebremichaelMKatzTHerbstRYoussoufianHBurtnessBEGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neckJ Clin Oncol.2007P I. Vol 25, No. 18S(June 20 suppl):abstr 6024.
   Google Scholar
• ChungCElyKMcGarvanLIncreased epidermal growth factor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomasJ Clin Oncol2006244170417616943533
   PubMed Web of Science ®Google Scholar
• LicitraLRollanFBokemeyerCBiomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHNJ Clin Oncol20092715S(suppl):abstr 6005.
   Web of Science ®Google Scholar
• ChungCSeeleyEGrigorievaJYarbroughWMass spectrometry profile as predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinomaJ Clin Oncol20092715S(suppl):abstr 6000.
   Web of Science ®Google Scholar
• ShinDMDonatoNJPerez-SolerREpidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancerClin Cancer Res200171204121311350885
   PubMed Web of Science ®Google Scholar
• WordenFPKumarBLeeJSChemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy numberJ Clin Oncol2008263138314618474879
   PubMed Web of Science ®Google Scholar
• KumarBCordellKGLeeJSEGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancerJ Clin Oncol2008263128313718474878
   PubMed Web of Science ®Google Scholar
• PsyrriAGouverisPVermorkenJHuman papillomavirus-related head and neck tumors: clinical and research implicationCurr Opin Oncol20092120120519370803
   PubMed Web of Science ®Google Scholar